No Data
No Data
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
BTIG analyst Thomas Shrader maintains $INmune Bio(INMB.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 37.3% and a total ave
INmune Bio's Unique Alzheimer's Trial Endpoint Receives Validation
Express News | INmune Bio Inc: Interim Analysis, Performed by a Third-Party, Demonstrated No Need to Change Trial Design or Size
Express News | INmune Bio Inc: Planned Interim Analysis Confirms Accuracy of SAMPLE Size Calculations and Statistical Power for Emacc, Primary Endpoint
Express News | INmune Bio Completes Blinded Interim Analysis Of Its Phase II Alzheimer's Disease Trial, Says 'The Planned Interim Analysis Confirms the Accuracy of the Sample Size Calculations and Statistical Power for EMACC, the Primary Endpoint.'
Express News | INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial